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Striatal Glutamate Release in L-DOPA-Induced Dyskinetic
Animals
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Abstract
L-DOPA-induced dyskinesia is a common side effect developed after chronic treatment with 3,4-dihydroxyphenyl-L-alanine
(L-DOPA) in Parkinson’s disease. The biological mechanisms behind this side effect are not fully comprehended although
involvement of dopaminergic, serotonergic, and glutamatergic systems has been suggested. The present study utilizes in
vivo amperometry to investigate the impact from unilateral 6-hydroxydopamine lesions and L-DOPA (4 mg/kg, including
benserazide 15 mg/kg) -induced dyskinetic behavior on striatal basal extracellular glutamate concentration and potassium-
evoked glutamate release in urethane-anesthetized rats. Recordings were performed before and after local L-DOPA
application in the striatum. In addition, effects from the 5-HT1A receptor agonist (2R)-(+)-8-hydroxy-2-(di-n-propylamino)te-
tralin hydrobromide (8-OHDPAT; 1 mg/kg) was assessed on glutamate release and on dyskinetic behavior. The results
revealed a bilateral ,30% reduction of basal extracellular glutamate concentration and attenuated potassium-evoked
glutamate release after a unilateral dopamine-depletion in L-DOPA naı¨ve animals. In dyskinetic subjects, basal glutamate
concentration was comparable to normal controls, although potassium-evoked glutamate release was reduced to similar
levels as in drug naı¨ve dopamine-lesioned animals. Furthermore, acute striatal L-DOPA administration attenuated glutamate
release in all groups, except in the dopamine-lesioned striatum of dyskinetic animals. Co-administration of 8-OHDPAT and L-
DOPA decreased dyskinesia in dopamine-lesioned animals, but did not affect potassium-evoked glutamate release, which
was seen in normal animals. These findings indicate altered glutamate transmission upon dopamine-depletion and
dyskinesia.
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Introduction
Patients with Parkinson’s disease are treated with 3,4-dihydrox-
yphenyl-L-alanine (L-DOPA) in order to improve motor function.
Although providing satisfactory relief of motor symptoms at early
stages of the treatment, side effects referred to as L-DOPA-induced
dyskinesia (LID) are seen in the majority of patients after several
years of chronic L-DOPA treatment. LID manifests as uncontrol-
lable, involuntary movements and affects up to 40% of the patients
after 4–6 years and as many as 90% of the patients after 9 years of
treatment with L-DOPA [1]. The biological mechanisms respon-
sible for the upcoming of LID are not fully understood to this date,
but the involvement of several distinct neurotransmitter systems
has been established [2]. Apart from the dopaminergic, the
serotonergic (5-HT; 5-hydroxytryptamine) and glutamatergic
system have been pointed out as two likely key-players.
The 5-HT system, with origin in the raphe nuclei, has been
suggested as the neuronal structure responsible for the upcoming
of LID, mainly since these neurons have the ability to convert L-
DOPA to dopamine as well as store and release dopamine
[3,4,5,6,7,8,9]. It has further been proposed that dopamine release
from 5-HT nerve terminals in the dopamine-lesioned striatum
would give rise to fluctuating striatal dopamine levels and thus
result in pulsatile postsynaptic receptor stimulation and the
development of LID. In line with this hypothesis, it has been
demonstrated that lesion of the 5-HT system or decreased 5-HT
neuron activity via autoreceptor activation attenuates dyskinetic
behavior in animal models of LID [10,11]. The mechanisms
referred to is that the dopamine levels are reduced and thereby
LID is counteracted, indicating that the dopamine levels are
abnormally high in the striatum of dyskinetic animals. However,
the release of dopamine after acute L-DOPA in dyskinetic animals
is reduced, which does not support this theory [12,13]. Further-
more, decreased 5-HT activity seems to be one of the pathological
features as it has been documented that in addition to the
dopaminergic degeneration, the 5-HT system degenerates in
parkinsonian patients [14,15,16]. In animal experiments, chronic
L-DOPA treatment decreases 5-HT and 5-HT metabolite levels in
several brain areas [17]. These observations raise the question
whether it is the dopamine derived from 5-HT neurons that gives
rise to LID, or if it might be dysmodulation of the 5-HT system.
Apart from the influence of the 5-HT system, increased
corticostriatal glutamate neurotransmission and receptor activa-
tion and function has been strongly associated with the upcoming
and maintenance of LID, as shown both in animal models and
patients [18,19,20,21,22,23]. It has been postulated that increased
corticostriatal signaling might contribute to abnormal motor
performance by causing an imbalance between the striatal output
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pathways, and indeed, the overactivity of the dopamine D1-
receptor-mediated direct pathway has been correlated to expres-
sion of LID [24,25,26,27,28]. In further support, several
investigations have provided evidence on relieved LID upon
antagonism on glutamate receptors [29,30,31,32,33,34,35,36],
and in fact, the only antidyskinetic drug currently used in patients
is the glutamate N-methyl-D-aspartate (NMDA) receptor antago-
nist amantadine [37,38]. However, dysregulation of the 5-HT
system may also affect the glutamate levels as the cortical neurons
express 5-HT1A receptors [39], and a 5-HT receptor agonist
inhibits striatal glutamate release [40,41,42]. Therefore, decreased
5-HT nerve terminal density in Parkinson’s disease may affect the
striatal glutamate influx. Thus, both the 5-HT and glutamatergic
system seems to be critically involved in the pathogenesis of LID,
however, the mechanisms for interaction between these circuits
are still elusive. The aims of the present study were to further
investigate the effects from dopamine depletion, chronic L-DOPA
treatment, and 5-HT1A receptor stimulation on striatal glutamate
levels. For these purposes, in vivo amperometry was employed for
subsecond quantification of basal glutamate concentration and
glutamate release in the striatum of urethane-anesthetized drug
naı¨ve hemiparkinsonian and chronically L-DOPA-treated dyski-
netic rats. Data were collected before and after acute striatal L-
DOPA infusion and the 5-HT1A receptor agonist (2R)-(+)-8-
hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OHD-
PAT) was co-administered to evaluate the impact of 5-HT1A
receptor activation during L-DOPA loading on striatal glutamate
concentration. Furthermore, a behavioral study was carried out to
evaluate effects of 8-OHDPAT on LID.
Materials and Methods
Animals
Female Sprague-Dawley rats (Taconic Farms Inc.; Denmark)
were used in this study. Animals were treated and housed in
accordance with internationally accepted guidelines and all
experiments had been approved by the local ethics committee,
Umea˚ Ethics Committee for Animal Studies (permit number: A23-
08). Food and water was provided ad libitum and animals were
housed under 12:12 h light-dark conditions. For the experimental
setup, animals of similar age were divided into three separate
treatment groups that constitute of unilateral 6-OHDA-lesioned
animals that received either chronic L-DOPA (n = 14) or vehicle
(0.9% NaCl; n = 5) injections, and normal rats receiving vehicle
(n = 6), see Fig. 1a.
Chemicals
Drugs and chemicals used throughout this study were purchased
from Sigma (Stockholm, Sweden), except the enzyme L-glutamate
oxidase (Seikagaku, US Biologicals, Massachusetts, USA) and the
5-HT1A agonist 8-OHDPAT (TOCRIS Bioscience, BioNuclear
Scandinavia AB, Stockholm, Sweden). All physiologically (in vivo)
applied solutions were dissolved in 0.9% NaCl (pH = 7.4), whereas
the standard solutions for calibration and coatings i.e. solutions for
in vitro use were dissolved in distilled deionized water.
6-OHDA injection and apomorphine-induced rotational
behavior
Dopamine depletions were performed according to the 6-
hydroxydopamine (6-OHDA) rat model [43]. When performing
the dopamine lesion, animals (,150 grams) were anesthetized with
4% isoflurane and placed in a stereotaxic frame. An incision was
made in the scalp and a hole was drilled in the skull at 4.4 mm
posterior and 1.2 mm lateral from the bregma position. A
Hamilton needle was lowered 27.8 mm below the dura mater
and 8 mg of 6-OHDA (dissolved in 4 ml saline containing 0.02%
ascorbic acid) was injected into the medial forebrain bundle at a
rate of 1 ml/min. The needle was left in place for 3 min before
being withdrawn.
Two weeks after the intracerebral 6-OHDA-injections, rats
were evaluated for apomorphine-induced rotational behavior in
order to determine lesion severity. Rats were placed in separate
bowls and left to acclimatize for approximately 15 min before
receiving a subcutaneous injection of 0.05 mg apomorphine/kg
bodyweight. Total contralateral turns to the lesioned hemisphere
were counted, and animals that made .450 turns during 70 min
were included in this study. It has previously been demonstrated
that this value corresponds to at least 90% striatal dopamine-
depletion [44].
L-DOPA treatment and dyskinesia ratings
Rats with severe dopamine lesions received chronic L-DOPA
treatment (4 mg/kg) plus benserazide-hydrochloride (15 mg/kg)
or vehicle beginning at 1.5 months after the dopamine depletion.
The animals were given L-DOPA or vehicle once daily for 14 days
and were evaluated for the expression of abnormal involuntary
movements (AIMs) on days 1, 4, 7, 10, and 14 according to
previously described protocols [45]. Briefly, rats were injected
subcutaneously (2 ml/kg bodyweight) with L-DOPA or vehicle
and placed in separate cages. The animals were evaluated for the
expression of axial, orolingual, and forelimb AIMs for 1 min every
20th min during 3 h, starting 20 min after the injection. Scores
from 0–4 were given for each subtype based on its severity and
duration (0 = not present, 1 = present during less than half of the
observation time, 2 = present during more than half of observation
time, 3 = continuous, but interrupted by external distraction,
4 = continuous, not interrupted by external distraction), thus the
total maximum score per animal during one session is 108.
Animals were considered dyskinetic when displaying scores of $2
on at least two of the three subtypes during one observation
period. Following 14 days of daily treatment, rats received L-
DOPA 2–3 times per week and the AIMs ratings were carried out
every 10th day to ensure stable status of dyskinesia. The dyskinetic
animals included in the amperometric and behavioral studies
expressed total AIMs scores of 38.7166.89 and 41.6765.53,
respectively, at their last testing session. Animals received their last
L-DOPA injection 2 days before electrochemical recordings.
Recordings were performed between 4–8 months after the
initiation of L-DOPA/vehicle treatment, and all animals were
age-matched. For the behavioral study, 8-OHDPAT (1 mg/kg)
was subcutaneously administered 5 min prior to L-DOPA.
Behavioral assessments with 8-OHDPAT were performed be-
tween 8 months after the initiation of L-DOPA/vehicle treatment.
In vivo amperometry
Preparation and calibration of electrodes. A detailed
description of the entire methodological process of in vivo
amperometric recordings of glutamate (preparation of electrodes,
calibration, and recordings in vivo etc.) has been published
previously and was followed with some minor modifications
[46]. In vivo amperometry was conducted with enzyme-coated
ceramic-based microelectrode arrays [47,48] to monitor basal
glutamate concentration and glutamate release in anesthetized
animals. A self-reference recording technique was employed to
selectively measure glutamate by removing background noise and
non-specific signals from interfering molecules [49]. Electrodes
(Thin-Film Technologies, Inc., Buellton, CA, USA) with four
recording sites (333615 mm) arranged as two pairs (sites separated
Glutamate Release in Dyskinesia
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by 30 mm for each pair) were prepared so that one pair of
recording sites were able to detect glutamate whilst the other pair
of channels, located 100 mm from the first pair, acted as sentinel
sites. The glutamate recording sites were coated with a solution of
L-glutamate oxidase (1%), bovine serum albumin (BSA, 1%), and
glutaraldehyde (0.125%). Hence, when glutamate reaches the
electrode surface, it is degraded by the L-glutamate oxidase into a-
ketoglutarate and hydrogen peroxide (H2O2), where the latter
molecule is oxidized and the electrons freed in this process is
detected by the electrode [50]. The sentinel sites were coated with
a BSA/glutaraldehyde solution, thus resulting in a protein layer
with similar properties as at the recording sites but lacking the
ability to record glutamate. Consequently, the current recorded by
the sentinel sites subtracted from the current recorded by the
glutamate detecting sites results in a signal specific for glutamate.
After the coating procedure, electrodes were let to dry for at least
72 h in a dry and clean atmosphere. An additional coating
procedure was applied where all four recording sites were
electroplated with 1,3-phenylenediamine (m-PD, 5 mM) to block
interfering molecules, such as ascorbic acid, from reaching the
recording sites by size-exclusion. The electrodes were utilized for
amperometric recordings earliest 24 h after the electroplating
procedure.
Amperometric recordings were preceded by a calibration
procedure where the electrode properties were challenged to
ensure selective detection of glutamate. Electrodes were calibrated
in 40 ml phosphate buffered saline (PBS, 0.05 M, pH = 7.4) at
37uC against an Ag/AgCl reference electrode. A constant
potential of 0.7 V was applied at 2 Hz using the Fast Analytical
Sensing Technology (FAST-16) system and software (Quanteon,
LLC, Nicholasville, KY, USA) and the signal was amplified 5006
(2 nA/V) via the headstage. Standard solutions of ascorbic acid
and glutamic acid were added to the beaker to produce a final
concentration of 250 mM of ascorbic acid and 60 mM of glutamic
acid, where the latter was achieved by three subsequent 20 mM
increments (Fig. S1). The resulting current produced upon each
addition was measured and electrodes were included when
detecting glutamate in a linear manner (R2.0.99) with selectivities
of .20:1 over ascorbic acid, and with a limit of detection ,2 mM
with a signal-to-noise level set at 3:1. The electrodes utilized in the
present study expressed selectivities of 66.90569.112 over ascorbic
acid, limit of detection of 0.77460.110 and R2 0.99860.001.
Standard solutions of dopamine and H2O2 were added to the
Figure 1. Illustration of the study design (a) and experimental setup during in vivo recordings of basal glutamate concentration and
glutamate release stimulated by KCl-ejections (K+) before and after striatal L-DOPA application (b) and the administration of 8-
OHDPAT (c).
doi:10.1371/journal.pone.0055706.g001
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beaker (2 and 8.8 mM, respectively) at the end of the calibration, to
assure impermeability of larger molecules and to test electrode
sensitivity to the reporter molecule H2O2.
In vivo recordings. Two micropipettes with tip diameters of
10–15 mm were filled with potassium chloride (KCl, 70 mM) and
L-DOPA (2.5 mM) respectively, and mounted parallel to each
other with sticky wax (Kerr Lab Corporation, Orange, CA, USA).
The micropipettes were then mounted at a distance of 50–100 mm
from the electrode surface in a centered position between the four
recording sites. The tip of the electrode/micropipette-assembly
was placed in PBS until used for in vivo recordings.
Animals were anesthetized with urethane (1.25–1.5 g/kg, i.p.).
When under surgical anesthesia, animals were tracheotomized to
facilitate spontaneous breathing and placed in a stereotaxic frame.
The scalp was removed and two holes were made with a dental
drill in the bone overlying the striatum bilaterally. An additional
burr hole was made caudally, at a position remote from the
recording sites, for insertion of a miniature Ag/AgCl electrode.
The dura mater was removed before lowering the electrode into
the striatum with a microdrive. Recordings were performed at four
striatal positions in each hemisphere (ML: 62.6 mm, AP: 60/
+1 mm, DV: 23.5 and 24.5 mm, calculated from the bregma).
At each striatal recording site, a stable baseline was acquired, and
then basal glutamate concentration and glutamate release was
recorded before and after local infusion of L-DOPA, thus,
monitoring effects on glutamate levels during OFF and ON L-
DOPA. When recording glutamate release, calibrated volumes of
KCl (100 nl) and L-DOPA (100 nl) was pressure-ejected at the
recording sites. KCl was ejected 4–5 times before and after a L-
DOPA ejection with 2-min intervals. Upon L-DOPA ejection,
10 min was let to pass before re-stimulating with KCl (Fig. 1b). It
has been demonstrated that L-DOPA can be taken up and
converted to dopamine during a 10-min period, and then being
released by KCl [13]. As a final challenge, in normal animals and
in the dopamine-lesioned striata of L-DOPA naı¨ve and dyskinetic
animals, L-DOPA loading was preceded (5 min) by a subcutaneous
injection of the 5HT1A receptor agonist 8-OHDPAT (1 mg/kg;
Fig. 1c). 8-OHDPAT was applied systemically to achieve an
overall effect by the 5-HT1A receptor agonist, while L-DOPA was
applied locally to monitor the glutamate levels in L-DOPA-free
and on-drug at each recording site. The hemisphere and striatal
position for the first measurement was alternated between the
subjects of each experimental group. The placement of the
electrodes was confirmed to be in the right position after the
recordings.
Statistical analysis
Processing of the raw data from recordings and calculations
were performed with the F.A.S.T Analysis software. In order to
determine basal extracellular glutamate concentration, the base-
line value was averaged over 30 sec before and after L-DOPA
infusion. This was performed by subtracting the current recorded
by the sentinel channel from the signal taken up by the recording
channel, hence providing assessment of the resting extracellular
glutamate concentration (mM). Upon each KCl-stimulation, an
increase in extracellular glutamate concentration was observed,
and the maximum glutamate concentration reached (calculated
from the baseline) was defined as the maximum peak amplitude
and referred to as glutamate release (mM).
Data were analyzed with one- or two-factor analysis of variance
(ANOVA), Student’s t-test, and paired t-test. Two-factor ANOVA
followed by Bonferroni post hoc test was performed to assess the
effects of the different treatment strategies between groups and the
effects of acute L-DOPA and 8-OHDPAT administrations on
glutamate levels. One-way ANOVA followed by Bonferroni post
hoc test, or Student’s t-test was carried out to assess individual
differences between and within groups, respectively. A paired t-test
was performed to assess the effects of 8-OHDPAT on LID. All
values are presented as mean values 6 standard error of mean,
and the significance level was set at p,0.05.
Results
Effects on basal extracellular glutamate concentration
In the striatum of normal vehicle-injected animals, the basal
extracellular glutamate concentration was measured to approx. 3–
4 mM before any drugs were applied (Fig. 2a). In the unilaterally
dopamine-depleted vehicle-treated animals, the glutamate levels
were decreased approx. 30% when compared to normal animals.
This effect was seen bilaterally i.e. both in the dopamine-depleted
(F = 5.442, p,0.001, two-factor ANOVA) and intact (p = 0.045)
striata and was most prominent after acute L-DOPA application
(F = 5.410, p = 0.026 in intact and p = 0.001 in lesioned striatum,
one-way ANOVA; Fig. 2a). Chronically L-DOPA-treated dyski-
netic animals displayed basal extracellular glutamate concentra-
tion that was comparable to those observed in normal animals
(Fig. 2a). It should also be noted that the acute L-DOPA
administration at the striatal recording site did not give rise to
changes in the basal glutamate concentration when comparing
with levels before L-DOPA loading in any of the groups examined
(p = 0.699). In summary, these findings demonstrate that lesioning
of the nigrostriatal dopamine system attenuates basal glutamate
concentration, not only in the dopamine-depleted striatum but
also in the contralateral hemisphere that still possesses an intact
dopamine innervation, when comparing with normal animals.
Upon chronic L-DOPA treatment of dopamine-lesioned animals,
on the other hand, the striatal glutamate concentration was similar
to levels recorded in normal animals.
Effects of L-DOPA on KCl-evoked glutamate release
Striatal KCl ejections (100 nl, 70 mM) gave rise to glutamate
release of varying amplitudes when comparing recordings
performed in different groups (F = 13.836, p,0.001, two-factor
ANOVA). In the unilaterally dopamine-depleted vehicle-treated
animals, significantly reduced amplitude of glutamate was
recorded bilaterally upon KCl ejections compared to normal
striatum (intact striatum p = 0.001 and lesioned striatum p,0.001;
Fig. 2b). More specifically, the attenuating effects were found
before acute L-DOPA administration in the dopamine-lesioned
striatum (F = 8.399, p,0.001, one-way ANOVA) and bilaterally
after the striatal L-DOPA loading (F = 6.361, p = 0.044 for intact
and p,0.001 for lesioned striatum, one-way ANOVA). A similar
observation was made in the dopamine-lesioned striatum of
chronically L-DOPA-treated dyskinetic animals, where the peak
amplitude for glutamate release was significantly reduced com-
pared to normal animals (F = 13.836, p,0.001, two-factor
ANOVA; Fig. 2b). The reduction in glutamate release was found
before L-DOPA administration (F = 8.399, p,0.001, one-way
ANOVA).
The acute striatal application of L-DOPA altered the peak
amplitude of KCl-evoked released glutamate (F = 16.114,
p,0.001, two-factor ANOVA), such that an attenuating effect
on glutamate release was observed in the striatum of normal
animals (t(198) = 2.569, p = 0.011; Fig. 2b,c) as well as in both
striata of unilaterally dopamine-depleted vehicle-treated animals
(t(106) = 3.256, p = 0.002 in intact and t(198) = 4.262, p,0.001 in
lesioned). A similar reduction was observed in the intact striatum
(t(25) = 2.233, p = 0.035), but not in the dopamine-lesioned
Glutamate Release in Dyskinesia
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Figure 2. Quantification (in mM) of basal extracellular glutamate concentration (a) and KCl-evoked glutamate release (b) before and
after acute L-DOPA administration in normal rats and in bilateral striata of vehicle- and L-DOPA-treated animals. Extracellular
glutamate concentration was estimated by averaging the baseline and glutamate release was observed upon KCl-ejections (K+) during in vivo
recordings, here in normal striatum (c) and dopamine-lesioned striatum of a dyskinetic subject (d). #p,0.05, ## p,0.01, and ###p,0.001
compared to before acute L-DOPA administration in the same group of animals. * p,0.05, ** p,0.01, and *** p,0.001 for comparisons between
groups with two-factor ANOVAs and 1 p,0.05, 11 p,0.01, and 111 p,0.001 for comparisons between groups with one-way ANOVA. Dopamine-
lesioned striata is abbreviated DA-les.
doi:10.1371/journal.pone.0055706.g002
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striatum of dyskinetic animals (t(92) = 0.387, p = 0.700; Fig. 2b, d).
To exclude that the diminishing effect of acute L-DOPA
administration on KCl-evoked glutamate release was not an
artifact produced by the ejected volume per se, local ejections with
vehicle (100 nl) was performed in the striatum of normal animals.
The results revealed that locally applied vehicle did not affect the
KCl-evoked glutamate release (t(18) = 0.104, p = 0.919).
Effects of a 5-HT1A receptor agonist on KCl-evoked
glutamate release and dyskinesia
Administration of 8-OHDPAT did not affect the basal
extracellular glutamate concentration in any of the treatments,
hence, the recorded glutamate levels were similar (p = 0.931) after
the administration of 8-OHDPAT in combination with L-DOPA
as seen before drugs or after acute L-DOPA administration.
To study the impact of 5-HT1A receptor activation during local
L-DOPA loading on KCl-evoked glutamate release, 8-OHDPAT
(1 mg/kg) was systemically administered 5 min prior to striatal
recordings were initiated (Figs. 1c and 3c). These trials were
performed in the dopamine-lesioned striata of vehicle- and
chronically L-DOPA-treated animals, respectively, and compared
with the effects seen in normal striatum (Fig. 3a). In the normal
striatum, administration of 8-OHDPAT and L-DOPA significantly
decreased glutamate release when compared to levels detected
before application of drugs (F = 10.634, p,0.001, one-way
ANOVA; Fig. 3a,c) and decreased glutamate release after local
L-DOPA administration (p = 0.029; Fig. 3a). Hence, the attenu-
ating effect of L-DOPA on glutamate release was further
potentiated by 8-OHDPAT in normal striatum. In the dopa-
mine-lesioned striata of both vehicle-treated and chronically L-
DOPA-treated animals, 8-OHDPAT did not alter the KCl-evoked
glutamate release compared to what was monitored after L-DOPA
alone (Fig. 3a).
During behavioral evaluation, the antidyskinetic effect of 8-
OHDPAT was demonstrated. Thus, injection of 8-OHDPAT
(1 mg/kg, s.c.) 5 min prior to L-DOPA (4 mg/kg, s.c.) significantly
reduced the AIMs scores (t(5) = 6.109, p = 0.002, paired t-test;
Fig. 3b).
Discussion
In this study, striatal basal glutamate concentration and release
were quantified utilizing in vivo amperometry with focus on effects
from a unilateral dopamine lesion and subsequent L-DOPA
treatment as well as the impact from 5-HT1A receptor activation.
The basal striatal extracellular glutamate concentration was
bilaterally attenuated in unilaterally dopamine-depleted animals,
whilst upon chronic L-DOPA treatment, similar glutamate levels
were observed as in normal controls. KCl-evoked glutamate
release was significantly decreased both in drug naı¨ve and
dyskinetic dopamine-lesioned animals when compared to normal
subjects. Moreover, acute administration of L-DOPA reduced
striatal glutamate release in normal and dopamine-lesioned drug
naı¨ve animals, while no effect was found in the dopamine-lesioned
striatum of dyskinetic animals. Co-administration of 8-OHDPAT
and L-DOPA further potentiated the decrease in normal animals
but not in dopamine-lesioned striatum, neither in dyskinetic nor in
L-DOPA naı¨ve animals.
Basal extracellular glutamate concentration was bilaterally
attenuated in unilaterally dopamine-depleted drug naı¨ve animals
when compared to normal controls. Previous investigations have
demonstrated contradictory results in the matter of striatal
glutamate activity upon a dopamine lesion, where increased
[51,52], decreased [53], and no effects [18,54,55,56] on glutamate
levels have been reported. These discrepancies might be a
consequence of the time point chosen for recordings following
the 6-OHDA lesion, as basal glutamate levels are decreased at
later stages post-dopamine lesions compared to earlier time points
[57]. In the present study, all recordings were performed 4–8
months post-lesion and thus, the reduced basal glutamate levels
might be a consequence of the later time point chosen for
recordings. Interestingly, the basal glutamate levels were neither
changed in dyskinetic animals nor were these affected by acute L-
DOPA application, although it has previously been reported that
chronic L-DOPA treatment increases the basal glutamate levels
which is seen during dyskinetic behavior [18,58]. The opposing
results might be explained by differences in methodologies used. In
microdialysis studies, the sampling time is up to 20 min while in
the present study, the KCl-evoked glutamate release and reuptake
occurred within 10 sec. Furthermore, the different results in
released glutamate may also reflect the different procedures for
application of acute L-DOPA, i.e. local application as in the
present study versus systemic injection [58]. Accordingly, the local
application might not give rise to the high levels accumulated after
systemic injection. However, the amount of L-DOPA applied
locally demonstrated effects on peak amplitude of glutamate in L-
DOPA naı¨ve animals, thereby implicating that the amount of L-
DOPA that was injected was sufficient to achieve an effect.
The bilateral effects on basal extracellular glutamate concen-
tration in the dopamine-depleted animals were unanticipated since
the animals received unilateral dopamine lesions. Accordingly, it
seems as the extracellular glutamate levels are regulated to gain
bilateral homeostasis, even though there are morphological
differences between the hemispheres. This could, with great
likelihood, occur when considering the fact that aside from the
ipsilateral corticostriatal projections, a significant proportion of the
corticostriatal afferents have their origin in the contralateral
hemisphere [59,60,61,62]. Additional interhemispheric connec-
tions are probably involved, as electrophysiological recordings
have demonstrated bilateral effects on neuronal activity of several
basal ganglia nuclei upon unilateral dopamine depletion [63]. In
addition, bilateral effects on glutamate levels in unilaterally
dopamine-depleted animals have indeed been demonstrated
before [52].
Administration of the NMDA receptor antagonist amantadine
hampers dyskinetic behavior [34,38,55,64,65]. Involvement of
glutamate in LID is further demonstrated using the more specific
NMDA receptor antagonist MK801 [66] as well as the
metabotropic glutamate receptor 5 (mGluR5) antagonist
[29,35,67], which also attenuates LID. Accordingly, blocking the
glutamate receptors ameliorates dyskinesia, at least partly,
indicating an antidyskinetic effect from regulation of the glutamate
release. In the present study, acute application of L-DOPA
reduced the amplitude of glutamate release in all striata, except in
the dopamine-lesioned hemisphere of dyskinetic animals. The
reason for the lack of effect in dyskinetic animals is still elusive,
however, amantadine also enhances the dopamine levels in the
dopamine-depleted striatum after L-DOPA injection [68]. The
striatal glutamate nerve terminals express dopamine D2 receptors
and activation of these receptors is believed to inhibit corticos-
triatal glutamate release [42]. Therefore the absence of effects of L-
DOPA, found in the present study, on glutamate release in the
dopamine-depleted striatum of dyskinetic animals might be an
indication of poor L-DOPA conversion, which has been demon-
strated previously [12,13,17]. In addition, the activity of the
enzyme that converts L-DOPA to dopamine is reduced in
dyskinetic animals [69] and further strengthens this theory. Thus,
the lack of reduction in glutamate release found in dyskinetic
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animals after L-DOPA loading support the behavioral studies
where glutamate receptor antagonists may reduce dyskinetic
behavior.
To evaluate the mechanisms by which the 5-HT1A receptor
agonist can reduce LID, as demonstrated here and by others, the
dose of 1 mg/kg 8-OHDPAT was utilized. This concentration was
chosen since doses of $0.2 mg/kg give rise to behavioral effects in
rats and marmosets referred to as serotonergic syndrome [10,70],
which is known to arise due to cortical 5-HT1A receptor
stimulation [39,71,72]. It has been demonstrated that the 5-
HT1A agonist inhibits striatal glutamate release and that direct
infusion of 8-OHDPAT into the primary motor cortex attenuates
LID [40,41,73]. One study illustrated both events, where systemic
administration of 8-OHDPAT at the same dose as used in the
present study not only attenuated LID but also the striatal
glutamate levels [58]. However, the action of the 5-HT1A receptor
agonist to counteract LID has also been referred to reduced
dopamine levels by inhibiting L-DOPA-generated dopamine
release from 5-HT nerve terminals [10,74,75]. In line with these
observations, the results presented here revealed that 8-OHDPAT
further attenuated the reduction in KCl-evoked glutamate release,
which was seen after L-DOPA application in normal animals,
while no effects were found in the dopamine-lesioned striata of
neither L-DOPA naı¨ve nor dyskinetic rats. Thus, even though the
5-HT1A receptor agonist may affect the glutamate release by direct
effects on the corticostriatal neurons, this was not the case in
dopamine-depleted striatum. In normal striatum, dopamine can
be released from intact dopamine nerve fibers and thereby reduce
glutamate release via the D2 receptors on the corticostriatal
glutamate fibers, while dopamine release generated from exoge-
nous L-DOPA in the dopamine-depleted striatum is inhibited by
the 5-HT1A receptor agonist. It has been reported that reduction
of LID can occur via synergistic actions of a NDMA antagonist
and 8-OHDPAT [76]. The administration of 8-OHDPAT did not
affect glutamate release in the present study, which could be
assigned that the local administration of L-DOPA might give
Figure 3. The effects of systemically administered 8-OHDPAT on KCl-evoked (K+) glutamate release (mM) during striatal L-DOPA-
loading in normal and dopamine-lesioned striata of vehicle- and L-DOPA-injected animals (a) and on AIM scores in dyskinetic
animals (b). 8-OHDPAT, systemically administered 5 min prior to striatal L-DOPA ejection, further reduced glutamate release seen after local L-DOPA
application in normal (a, c), but not in dyskinetic animals, even though dyskinetic behavior was attenuated (b) when applying the drugs systemically.
# p,0.05 and ### p,0.001 compared to before acute L-DOPA administration in the same group of animals. * p,0.05 and *** p,0.001 for
comparisons between groups with 2-factor ANOVA, within groups with one-way ANOVA, and paired t-test. 1 p,0.05, 111 p,0.001 for comparisons
between groups with one-way ANOVA. Dopamine-lesioned striata is abbreviated DA-les.
doi:10.1371/journal.pone.0055706.g003
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insufficient doses, however, it is not likely since it was possible to
regulate glutamate release in normal animals. While this serves
explanatory for the effects of 5-HT1A receptor agonist on
glutamate release, it is still elusive whether it is dopamine or
glutamate that is the most important neurotransmittor to be
regulated in LID. Most likely it is a combination since dopamine
D1 and NMDA receptor complexes are downregulated in
dyskinesia [77].
In conclusion, the present study demonstrates that glutamate
release is reduced in the dopamine-depleted striatum, and that L-
DOPA application can further attenuate the glutamate release in
dopamine-lesioned striatum of drug naı¨ve but not in dyskinetic
animals. These data indicate that glutamate levels are not different
in dopamine-lesioned drug naı¨ve and dyskinetic animals, although
there is a loss of regulation of glutmate levels upon L-DOPA
administration in dyskinetic animals. This work thereby support
behavioral studies where glutamate receptor antagonists may
reduce dyskinetic behavior by blocking the input on postsynaptic
glutamate receptors on the striatal output neurons, as the critical
mechanism to counteract LID might be regulation of glutamate
levels. Furthermore, 8-OHDPAT did not affect the glutamate
release in dopamine-depleted striatum, suggesting that the effects
of 8-OHDPAT when reducing dyskinetic behavior is not a
consequence from regulation of the glutamate input to the
striatum.
Supporting Information
Figure S1 Calibration of microelectrode arrays. The
electrodes were coated with glutamate oxidase and 1,3-phenyl-
enediamine, resulting in selective recordings of glutamate (Glu,
20 mM per addition) by blocking larger molecules, such as ascorbic
acid (AA, 250 mM) and dopamine (DA, 2 mm) from the electrode
surface. The reporter molecule for the degradation of glutamate
by glutamate oxidase, hydrogen peroxide (H2O2, 8.8 mM), was
added to the calibration beaker to assure detection by the
electrode.
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